Astrazeneca vs GSK
Astrazeneca is the larger business, with $58.74bn of revenue in fiscal 2025 against $43.09bn for GSK (1.4 times as much). Astrazeneca grew faster (8.6% against 7.5%). GSK kept more of each dollar of sales as profit: a net margin of 17.5% against 17.4%. Astrazeneca carries less debt relative to equity (60.9% against 108.2%).
| Latest fiscal year | AstrazenecaAZN, 2025 | GSKGSK, 2025 |
|---|---|---|
| Revenue | $58.74bn | $43.09bn |
| Revenue growth | 8.6% | 7.5% |
| Net income | $10.22bn | $7.54bn |
| Operating margin | 23.4% | 24.3% |
| Net margin | 17.4% | 17.5% |
| Return on equity | 22.9% | 38.5% |
| Free cash flow | $11.77bn | $8.43bn |
| Cash | $5.71bn | $4.57bn |
| Total debt | $29.62bn | $23.83bn |
| Debt to equity | 60.9% | 108.2% |
| Dividend per share | — | — |
| Dividend yield | 1.7% | — |
| Share buybacks | $521m | $1.82bn |
| Employees | — | — |
| Market value | $286.25bn | $100.19bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 1 sales | 0 buys, 0 sales |